Finance
Nabi's first quarter earnings in line with expectations
Published in Vaccine Weekly, May 29th, 2002
The company reported a net loss for the period, which totaled $0.7 million, or $0.02 per share on a fully diluted basis. The gross margin earned on product sales increased to $14.1 million, or 34% of total sales in 2002, from $13.6 million, or 23% of total sales, in the first quarter of 2001. This improvement reflects increased sales of Nabi-HB [hepatitis B immune globulin (human)], and improvement in the mix of biopharmaceutical sales and antibody sales.
"We continued to leverage the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2002-05-29)
More Articles from Vaccine Weekly
- Immunology
Research in fungal pathogenesis offers new hope of vaccine strategies for immunosupressed patients - Vaccine Response
High hepatitis C virus load negates effective response to hepatitis B vaccine - End-Stage Kidney Disease
Agent renders hepatitis B vaccine more effective in hemodialysis patients - Multiple Myeloma
Extra cytokines can improve idiotype vaccination efficacy - Tumor Vaccine
Transfection strategy improves dendritic cell-based tumor suppression - AIDS Vaccine
Vaccine candidates clear review; phase III results expected within month - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
